NAD+ Therapeutics and Skeletal Muscle Adaptation to Exercise in Humans
Open Access
- 4 November 2022
- journal article
- review article
- Published by Springer Science and Business Media LLC in Sports Medicine
- Vol. 52 (S1), 91-99
- https://doi.org/10.1007/s40279-022-01772-2
Abstract
Nicotinamide adenine dinucleotide (NAD+) is a vital energy intermediate in skeletal muscle. The discovery of dietary-derived NAD+ precursors has led to the rapid development of NAD+ therapeutics designed to manipulate NAD+ content in target tissues. Of those developed, nicotinamide riboside and nicotinamide mononucleotide have been reported to display health benefit in humans under clinical scenarios of NAD+ deficiency. In contrast, relatively little is known regarding the potential benefit of nicotinamide riboside and nicotinamide mononucleotide supplementation in healthy individuals, with questions remaining as to whether NAD+ therapeutics can be used to support training adaptation or improve performance in athletic populations. Examining animal and human nicotinamide riboside supplementation studies, this review discusses current evidence suggesting that NAD+ therapeutics do not alter skeletal muscle metabolism or improve athletic performance in healthy humans. Further, we will highlight potential reasons why nicotinamide riboside supplementation studies do not translate to healthy populations and discuss the futility of testing NAD+ therapeutics outside of the clinical populations where NAD+ deficiency is present.Keywords
Funding Information
- Rebecca L. Cooper Medical Research Foundation
- National Health and Medical Research Council (2013278)
This publication has 59 references indexed in Scilit:
- Skeletal muscle-specific overexpression of SIRT1 does not enhance whole-body energy expenditure or insulin sensitivity in young miceDiabetologia, 2013
- PGC-1α is Dispensable for Exercise-Induced Mitochondrial Biogenesis in Skeletal MusclePLOS ONE, 2012
- The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced ObesityCell Metabolism, 2012
- Sirtuin 1 (SIRT1) Deacetylase Activity Is Not Required for Mitochondrial Biogenesis or Peroxisome Proliferator-activated Receptor-γ Coactivator-1α (PGC-1α) Deacetylation following Endurance ExerciseOnline Journal of Public Health Informatics, 2011
- Nuclear SIRT1 activity, but not protein content, regulates mitochondrial biogenesis in rat and human skeletal muscleAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human CellsOnline Journal of Public Health Informatics, 2011
- The deacetylase enzyme SIRT1 is not associated with oxidative capacity in rat heart and skeletal muscle and its overexpression reduces mitochondrial biogenesisJournal Of Physiology-London, 2009
- Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1αThe EMBO Journal, 2007
- Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.JCI Insight, 1991
- The alcoholic ferment of yeast-juice. Part II.—The coferment of yeast-juiceProceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 1906